Predictions
Microsoft Corp.
Start price
Target price
Perf. (%)
€199.10
30.03.21
30.03.21
€250.00
30.03.22
30.03.22
42.64%
30.03.22
30.03.22
Exxon Mobil Corp.
Start price
Target price
Perf. (%)
€48.21
26.03.21
26.03.21
€75.00
26.03.22
26.03.22
59.74%
28.03.22
28.03.22
Walt Disney Co.
Start price
Target price
Perf. (%)
€156.26
25.03.21
25.03.21
€115.00
25.03.22
25.03.22
-18.71%
26.03.22
26.03.22
Microsoft Corp.
Start price
Target price
Perf. (%)
€200.20
25.03.21
25.03.21
€240.00
25.03.22
25.03.22
18.38%
19.07.21
19.07.21
Johnson & Johnson
Start price
Target price
Perf. (%)
€136.62
24.03.21
24.03.21
€145.00
24.03.22
24.03.22
-1.26%
09.04.21
09.04.21
Known brand
Future proof or reliable business model
Medium risks for its business
Apple Inc.
Start price
Target price
Perf. (%)
€102.28
20.03.21
20.03.21
€120.00
20.03.22
20.03.22
45.19%
20.03.22
20.03.22
Could be very worthwhile Investment >20% year
Apple Inc.
Start price
Target price
Perf. (%)
€102.28
20.03.21
20.03.21
€102.50
20.03.22
20.03.22
45.19%
20.03.22
20.03.22
Known brand
Market Leader or Top 3
Coca-Cola Co.
Start price
Target price
Perf. (%)
€42.48
19.03.21
19.03.21
-
19.03.22
19.03.22
0.99%
22.03.21
22.03.21
Could be worthwhile Investment >10% per year
Apple Inc.
Start price
Target price
Perf. (%)
€101.02
19.03.21
19.03.21
-
19.03.22
19.03.22
0.38%
19.03.21
19.03.21
Risky Investment
Coca-Cola Co.
Start price
Target price
Perf. (%)
€43.17
17.03.21
17.03.21
€52.00
-0.61%
20.03.21
20.03.21
Market Leader or Top 3
Could be worthwhile Investment >10% per year
Well known brand
Johnson & Johnson
Start price
Target price
Perf. (%)
€135.56
16.03.21
16.03.21
€140.00
-0.53%
23.03.21
23.03.21
Known brand
Future proof or reliable business model
Medium risks for its business
Pfizer Inc.
Start price
Target price
Perf. (%)
€29.35
15.03.21
15.03.21
€50.00
15.03.22
15.03.22
43.43%
09.11.21
09.11.21
Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
Apple Inc.
Start price
Target price
Perf. (%)
€102.22
15.03.21
15.03.21
€120.00
30.07.22
30.07.22
31.03%
17.11.21
17.11.21
Revenue growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Very capable Management